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Abstract
Primary coenzyme Q10 (CoQ10) deficiency is due to mutations in
genes involved in CoQ biosynthesis. The disease has been associ-
ated with five major phenotypes, but a genotype–phenotype
correlation is unclear. Here, we compare two mouse models with
a genetic modification in Coq9 gene (Coq9Q95X and Coq9R239X),
and their responses to 2,4-dihydroxybenzoic acid (2,4-diHB).
Coq9R239X mice manifest severe widespread CoQ deficiency asso-
ciated with fatal encephalomyopathy and respond to 2,4-diHB
increasing CoQ levels. In contrast, Coq9Q95X mice exhibit mild CoQ
deficiency manifesting with reduction in CI+III activity and mito-
chondrial respiration in skeletal muscle, and late-onset mild
mitochondrial myopathy, which does not respond to 2,4-diHB. We
show that these differences are due to the levels of COQ biosyn-
thetic proteins, suggesting that the presence of a truncated
version of COQ9 protein in Coq9R239X mice destabilizes the CoQ
multiprotein complex. Our study points out the importance of
the multiprotein complex for CoQ biosynthesis in mammals,
which may provide new insights to understand the genotype–
phenotype heterogeneity associated with human CoQ deficiency
and may have a potential impact on the treatment of this mito-
chondrial disorder.
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Introduction
Coenzyme Q (CoQ) is an essential molecule for mitochondrial ATP
synthesis and other metabolic processes (Turunen et al, 2004;
Garcia-Corzo et al, 2013). Its endogenous biosynthesis occurs ubiq-
uitously in the mitochondria and starts with the formation of a
4-hydroxybenzoate (4-HB) head group and a lipophilic polyisopre-
noid tail. While the quinone ring is derived from tyrosine or
phenylalanine, the isoprenoid side chain is produced by addition
of isopentenyl diphosphate molecules to farnesyl diphosphate or
geranylgeranyl diphosphate in multiple steps catalyzed by polyprenyl
diphosphate synthase (PDSS1–PDSS2). Then, 4-para-hydroxybenzoate:
polyprenyl transferase, encoded by Coq2, mediates the conjugation
of the aromatic ring precursor, 4-HB, to the side chain, while
five other enzymes, encoded by Coq3 to Coq7, reside in the
mitochondrial inner membrane and modify the quinone ring of CoQ
(Supplementary Fig S1) (Tran & Clarke, 2007). Other proteins are
thought to have regulatory functions in the CoQ biosynthetic path-
way: (i) COQ9 is essential for the function of COQ7, an enzyme that
catalyzes the hydroxylation of demethoxyubiquinone to produce
5-hydroxyquinone (Garcia-Corzo et al, 2013); (ii) ADCK3 and
ADCK4 regulate other CoQ biosynthetic proteins by their kinase
activities (Tran & Clarke, 2007); and (iii) PTC7 regulates the activity
of COQ7 by its phosphatase activity (Martin-Montalvo et al, 2013).
Moreover, several studies have shown evidence that, in yeast, the
enzymes required for CoQ biosynthesis are organized in a multipro-
tein complex. This organization would allow channeling of labile/
reactive intermediates, enhance catalytic efficiency, and provide a
mechanism for coordinative regulation of components (Tran &
Clarke, 2007). However, there is no proof of the existence of a
multiprotein complex for CoQ biosynthesis in mammals.
Mutations in CoQ biosynthetic genes produce primary CoQ10
deficiency, a mitochondrial syndrome with five major clinical
presentations: (i) encephalomyopathy with brain involvement and
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recurrent myoglobinuria; (ii) infantile multisystem disorder with
encephalopathy usually associated with nephropathy and variable
involvement of other organs; (iii) ataxic syndrome with cerebellar
atrophy; (iv) isolated myopathy; and (v) steroid-resistant nephrotic
syndrome (Emmanuele et al, 2012). Moreover, mutations in COQ2
have been recently reported in Japanese patients with multiple
system atrophy (Multiple-System Atrophy Research, 2013). The
causes of this clinical variability are unknown, and it is difficult to
explain why mutations in the same gene may cause different
phenotypes, for example, mutations in COQ2 and COQ6 have been
associated with isolated nephropathy or multisystemic disease
(Quinzii et al, 2006; Diomedi-Camassei et al, 2007; Heeringa et al,
2011; Jakobs et al, 2013), due to the limited number of patients
described.
To better understand the pathophysiologic consequences of
primary CoQ10 deficiency, we recently generated a mouse model
carrying a homozygous mutation in Coq9 gene (R239X, Coq9R239X).
This mutation is homologue to the human R244X mutation
(Duncan et al, 2009). Coq9R239X mice showed widespread CoQ
deficiency (Garcia-Corzo et al, 2013), and their characterization
demonstrated that: (i) the presence of a dysfunctional COQ9
protein and/or the deficit in CoQ in the brain causes an increase
in free complex III, leading to a decrease in mitochondrial respira-
tion and ATP synthesis, (ii) mitochondrial dysfunction in the brain
induces oxidative damage and a caspase-independent apoptotic cell
death, and (iii) the encephalomyopathic form of CoQ deficiency is
progressive and takes place with neuronal death, severe reactive
astrogliosis and spongiform degeneration. Therefore, Coq9R239X
mice show clinical, histopathological, biochemical and molecular
signs of a fatal mitochondrial encephalomyopathy (Garcia-Corzo
et al, 2013).
To understand the molecular mechanisms underlying the
genotype–phenotype correlation in CoQ deficiency, we have gener-
ated and characterized at biochemical, molecular and clinical level a
new mouse model with a different genetic defect in the same Coq9
gene, specifically, a homozygous Coq9 Q95X mutant (Coq9Q95X), to
compare with the Coq9R239X mouse model.
Results
Lack of the Coq9 protein causes moderate CoQ deficiency
Coq9Q95X mice pups had normal development and were indistin-
guishable from wild-type mice (Coq9+/+). As described in the
Coq9R239X, by postnatal day 21, Coq9Q95X mice had also lost their
body hair (Fig 1A), which grew back during the next hair growth
cycle.
To prove that wild-type COQ9 protein was not produced in
Coq9Q95X mice, we first performed an immunoblotting analysis
using two different anti-COQ9 antibodies: one against amino acids
165–318, to map the C-terminal region of the protein (sc-271892),
and the other against amino acids 160–190, corresponding to a
region within internal sequence of the COQ9 protein (ab-104189).
No protein was detected in Coq9Q95X mice compared to wild-type
(Fig 1B). To check whether the premature termination of the COQ9
protein induces the complete loss of the protein, we also performed
a proteomic analysis by high-resolution LC-MS/MS against six
identified peptides from the COQ9 protein, one of them being
(QQPPHSSSQQHSETQGPEFSRPPR) present in a possible truncated
version of the protein of 95 amino acids (Pagliarini et al, 2008).
Although COQ9 was clearly detected in the wild-type samples,
none of its peptides were observed in Coq9Q95X mice (Fig 1C),
demonstrating that the COQ9 protein was completely absent
in Coq9Q95X mice. In contrast, in Coq9R239X mice, a truncated
version of COQ9 protein was observed by Western blot using an
antibody against the internal sequence of the protein (Supplemen-
tary Fig S2).
The consequence of the lack of the COQ9 protein was a signifi-
cant decrease of both CoQ9 (the major form of ubiquinone in
rodents) and CoQ10 levels in all examined tissues (cerebrum, cere-
bellum, heart, kidney, extensor and triceps surae) of Coq9Q95X mice
compared with the age-mated Coq9+/+mice (Fig 2A–F and Supple-
mentary Fig S3A–F). While CoQ9 levels were around 50% in cere-
brum, cerebellum and heart (Fig 2A–C), kidney and skeletal muscle
had 30% of residual CoQ9 levels compared with wild-type animals
(Fig 2D–F).
An intriguing observation was that in all tissues, CoQ9 levels in
Coq9Q95X mice were higher compared with Coq9R239X mice, in which
residual CoQ9 levels were around 20% compared to wild-type
animals (Fig 3A–F). However, muscle was the tissue with more
similar CoQ9 levels between both models (Fig 3F).
Two distinctive mutations in the Coq9 gene induce different
changes in the Coq biosynthetic gene expression and
protein level
The differences found in CoQ9 levels between the Coq9
Q95X and
Coq9R239X mice may be due to differences in the expression of the
Coq genes or, alternatively, to differences in the stability of the CoQ
multiprotein complex manifested by different levels of COQ
proteins.
By virtue of that, we first determined mRNA expression levels
of some genes encoding proteins that are involved in CoQ
biosynthesis and are components of the CoQ mutiprotein
complex, that is, Coq9, Coq7, Coq6, Coq5 and Adck3, in
cerebrum, kidney and muscle from age-matched Coq9+/+,
Coq9Q95X and Coq9R239X mice.
In cerebrum and kidney, Coq9 mRNA levels were nearly unde-
tectable in Coq9Q95X compared with Coq9+/+ mice (1  0.38 and
1  0.90%, respectively) and significantly decreased in Coq9R239X
compared with Coq9+/+ mice (18  0.38 and 10  0.21%, respec-
tively) (Fig 4A and F). Similar levels of Coq7 and Coq5 mRNA
expression were detected in cerebrum and kidney of Coq9Q95X,
Coq9R239X and Coq9+/+ mice (Fig 4B, D, G and I), while Coq6 was
significantly decreased (72.1  4.35%) only in cerebrum of
Coq9Q95X compared with Coq9+/+ mice (Fig 4D); Adck3 was slightly
increased in kidney of Coq9R239X compared to Coq9Q95X (116  7.9
versus 85.1  20.6%) (Fig 4H). In muscle, Coq9 mRNA levels were
similarly decreased in both Coq9Q95X and Coq9R239X (3  0.9 and
0.5  0.2%) compared to Coq9+/+ mice (Fig 4K). Moreover, Adck3
and Coq5 mRNA levels were significantly decreased in Coq9Q95X
mice compared to Coq9+/+ mice (65.3  11.1% for Adck3 and
77.6  8.9% for Coq5) (Fig 4M and N). Comparing the two mutant
mice, it is remarkable that Coq9 mRNA expression levels in cere-
brum and kidney of Coq9R239X mice were significantly higher
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compared to Coq9Q95X (18.3  1.6 versus 1.3  0.4% in cerebrum
and 10.6  2.2 versus 1.3  0.9% in kidney) (Fig 4A and F). In
contrast, in muscle, there were no differences in Coq9 mRNA levels
between the two mutant models (Fig 4K). The degradation of the
mutant Coq9 mRNA in both mouse models (Coq9Q95X and
Coq9R239X) is due to nonsense-mediated mRNA decay (NMD) since
the treatment of mutant MEFs with cyclohexamide, an inhibitor of
NMD (Rio Frio et al, 2008), increased the levels of Coq9 mRNA in
Coq9Q95X (fold increase 5.5  1.1, treated/untreated) and Coq9R239X
(fold increase 21.4  6.8, treated/untreated) compared to the mild





Figure 1. Coq9Q95X mice at 21 postnatal days and analysis of COQ9 protein.
A Coq9Q95X mice at 21 postnatal days showing the loss of corporal hair.
B Representative Western blot images of COQ9 protein in kidney homogenate from Coq9+/+ (n = 4) and Coq9Q95X mice (n = 4) at 3 months of age. Antibody sc-271892
was used to map the C-terminal region of the COQ9 protein and antibody ab-104189 was used to map the internal sequence of the COQ9 protein.
C High-resolution LC-MS/MS proteomic analysis of kidney mitochondria from Coq9+/+ (n = 3) and Coq9Q95X mice (n = 3) at 3 months of age. None of the six peptides of
the COQ9 protein identified in Coq9+/+ mice was detected in Coq9Q95X mice.
Source data are available online for this figure.
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Secondly, we measured the levels of the CoQ biosynthetic
proteins encoded by these genes. In Coq9Q95X mice, steady-state
levels of COQ7 and COQ5 were significantly decreased in cerebrum
(19  9 and 41  13%), kidney (9  6 and 50  9%) and muscle
(16  3 and 17  6%) compared with Coq9+/+ mice. Coq9R239X
mice showed extremely reduced levels of COQ5 and COQ7 in cere-
brum (0.1  0.1 and 35  11%), kidney (0.1  0.1 and
38  14%), and muscle (undetectable, and 17  6%) compared to
Coq9+/+ mice (Supplementary Fig S4A and C; Fig 5A, C, E and G).
In cerebrum and muscle, ADCK3 levels were unchanged in
Coq9Q95X mice and decreased in Coq9R239X mice compared to Coq9+/+
mice (55  19 and 51  3%) (Supplementary Fig S4; Fig 5F). In
kidney, ADCK3 and COQ6 levels were significantly increased in
Coq9Q95X mice (162  18 and 179  20%) compared with Coq9+/+
mice and reduced in Coq9R239X mice compared with Coq9Q95X mice
(43  17% for ADCK3 and 31  9% for COQ6) (Fig 5B and D).
Muscle of Coq9Q95X mice also showed a significant decrease of COQ6
compared to Coq9+/+ mice (45  5%) (Fig 5H).
Consistent with the results obtained in Coq9R239X mice, human
skin fibroblasts carrying the R239X homologue mutation
(COQ9R244X) showed a reduction in COQ9, COQ7, ADCK3 and COQ5
protein levels (Supplementary Fig S5A–D).
Moderate CoQ deficiency in Coq9Q95X mice leads to impaired
mitochondrial bioenergetics function
To assess whether there was a direct correlation between the tissue
CoQ deficiency and the bioenergetics defect, we next evaluated CoQ
levels and mitochondrial respiratory chain function in isolated mito-
chondria from cerebrum, kidney and muscle of Coq9Q95X and
control mice at 6 months of age. Mitochondrial CoQ levels were
significantly decreased in cerebrum, kidney and muscle of Coq9Q95X
compared with Coq9+/+ mice (Fig 6A–C), and the level of CoQ
deficiency correlated with the CoQ levels measured in tissue
homogenates.
CoQ-dependent mitochondrial CI+III activity was considerably
reduced only in kidney and muscle of female Coq9Q95X mice, while
there were no differences in mutant males when compared with the
wild-type littermates (Fig 6D–F). On the contrary, CoQ-dependent
CII+III activities were comparable in mutant and control mice
(Fig 6G–I). These results correlate with the levels of CoQ because
the decrease in CI+III and CII+III activities were more pronounced
in Coq9R239X mice (Garcia-Corzo et al, 2013).
The analysis by blue native gel electrophoresis (BNGE)




Figure 2. Coq9Q95X mice showed moderate CoQ deficiency.
A–F CoQ9 levels in tissue homogenates from brain (A), cerebellum (B), heart (C), kidney (D), extensor (E) and triceps surae (F) of male and female Coq9
+/+ and Coq9Q95X
mice at 6 and 12 months of age. Data are expressed as mean  SD. Statistical analysis was performed on 6-month-old Coq9+/+ mice versus 6-month-old Coq9Q95X
mice and 12-month-old Coq9+/+ mice versus 12-month-old Coq9Q95X mice. **P < 0.01; ***P < 0.001. Student’s t-test (n = 8 for each group).
Source data are available online for this figure.
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subunit) antibody showed that the overall amount of complex III
substantially forming SC, as well as the free complex III, was
similar in cerebral, kidney and muscle mitochondria of Coq9Q95X
and Coq9+/+ mice (Fig 6J–L). These results differ from those in
Coq9R239X mice, where an increase of free complex III was
detected in cerebrum and kidney (Garcia-Corzo et al, 2013).
The bioenergetics defect in kidney and muscle of Coq9Q95X
mice was confirmed by measurement of mitochondrial O2
consumption using isolated mitochondria in the XFe24 Extracellu-
lar Flux Analyzer (Seahorse Bioscience). In kidney, the phos-
phorylating respiration (State 3o, in the presence of ADP and
substrates) showed a significant decrease in Coq9Q95X females
(82  6%), and Coq9R239X males and females (56  13 and
57  1%, respectively) compared with wild-type controls (Fig 7A
and B and Supplementary Fig S7A). In muscle, State 3o was
significantly decreased in Coq9Q95X (62  7% in males and
73  6% in females) and Coq9R239X mice (58  10% in males
and 44  4% in females) (Fig 7C and D and Supplementary Fig
S7B). In both mutant models, the percentage of decrease in the
ADP-stimulated respiration was higher in muscle than in kidney
(Fig 7A and C). Similar data were obtained in other respiratory
states, for example, basal respiration (State 2), resting respiration
(State 4, after the addition of oligomycin) and maximal
uncoupler-stimulated respiration (State 3u, after the addition of
FCCP) (Supplementary Figs S6A–F and S7A and B and Fig 7B
and D).
Morphological evaluation of Coq9Q95X mice
To assess whether the moderate CoQ deficiency and mitochondrial
bioenergetics impairment lead to structural changes in Coq9Q95X
mice tissues, we performed histopathological and histochemical
analysis of different sections from cerebrum, kidney and muscle at
different ages and compared them with the age- and sex-matched
Coq9+/+ littermates.
Hematoxylin and eosin (H&E) and Luxol fast blue (LFB) stains of
cerebrum did not show any structural abnormalities at 3 months of
age (Supplementary Fig S8A–D). Likewise, the periodic acid-Schiff
(PAS) stain did not reveal histologic alterations in kidney (Supple-
mentary Fig S8E and F). Further evaluation of kidney at 12 and
18 months of age did not show any anatomopathological changes
(Supplementary Fig S11A–H). These results, together with the
normal biomarkers levels obtained from urine albumin and urea
(Supplementary Table S1), suggest that Coq9Q95X mice did not mani-
fest evidence of kidney diseases associated with CoQ deficiency.
In triceps surae muscle, we observed round-shaped muscle fibers
with central nuclei in one Coq9Q95X female sample (out of six)
(Supplementary Fig S8G–J). To check whether this was an
isolated event or it was a sign of muscle pathology, we next
performed a histochemical examination of triceps surae in controls
and homozygous mutant mice at 3, 6, 12 and 18 months of age. In
younger Coq9Q95X mice (3–12 months old), cytochrome c oxidase




Figure 3. Coq9Q95X mice exhibited higher CoQ levels compared with Coq9R239X mice.
A–F Residual CoQ9 levels in tissue homogenates from brain (A), cerebellum (B), heart (C), kidney (D), liver (E) and skeletal muscle (F) of Coq9
+/+, Coq9Q95X and Coq9R239X
mice at 1, 3 and 5 months of age. Data are expressed as mean  SD. **P < 0.01; ***P < 0.001; Coq9Q95X and Coq9R239X mice versus Coq9+/+ mice. #P < 0.05;
##P < 0.01; ###P < 0.001; Coq9Q95X versus Coq9R239X mice (one-way ANOVA with a Tukey’s post hoc test; n = 8 for each group; numbers above columns indicate
P-values of the one-way ANOVA test).
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compared to Coq9+/+ littermates (Fig 8A, B, E and F and Supple-
mentary Fig S9A–H). Nevertheless, at 18 months, Coq9Q95X females
showed a higher number of COX- and SDH-negative fibers (Fig 8C,
D, G and H), suggesting that there was a shift from type I fibers
(slow-twitch) to type II fibers (fast-twitch). The Gomori trichrome
stain did not show signs of mitochondrial proliferation and scattered
ragged red fibers (RRF) (Fig 8I–L and Supplementary Fig S9I–L). No
changes in the overall architecture and general morphology were
detected by H&E stain (Fig 8M–P and Supplementary Fig S9M–P).
Immunohistochemistry with primary anti-glial fibrillary acid
protein (GFAP) antibody did not show significant changes in
the distribution and number of astrocytes in diencephalon
A B C D E
F G H I J
K L M N O
Figure 4. CoQ biosynthetic gene expression.
A–E mRNA expression levels of Coq9 (A), Coq7 (B), Adck3 (C), Coq5 (D) and Coq6 (E) on cerebrum of Coq9+/+, Coq9Q95X and Coq9Q95X mice at 3 months of age. **P < 0.01;
***P < 0.001; Coq9Q95X and Coq9R239X mice versus Coq9+/+ mice. ###P < 0.001; Coq9Q95X versus Coq9R239X mice.
F–J mRNA expression levels of Coq9 (F), Coq7 (G), Adck3 (H), Coq5 (I) and Coq6 (J) on kidney of Coq9+/+, Coq9Q95X and Coq9Q95X mice at 3 months of age. ***P < 0.001;
Coq9Q95X and Coq9R239X mice versus Coq9+/+ mice. #P < 0.05; ###P < 0.001; Coq9Q95X versus Coq9R239X mice.
K–O mRNA expression levels of Coq9 (K), Coq7 (L), Adck3 (M), Coq5 (N) and Coq6 (O) on triceps surae of Coq9+/+, Coq9Q95X and Coq9Q95X mice at 3 months of age.
*P < 0.05; ***P < 0.001; Coq9Q95X and Coq9R239X mice versus Coq9+/+ mice. #P < 0.05; Coq9Q95X versus Coq9R239X mice.
Data information: All values are presented as mean  SD. One-way ANOVA with a Tukey’s post hoc test. Numbers above columns indicate P-values of the one-way
ANOVA test (n = 5 for each group).
Table 1. Administration of cyclohexamide (CH) inhibits NMD in MEFs
from Coq9Q95X and Coq9R239X mice.
Coq9 mRNA (CH-treated/untreated)
Coq9+/+ 1.54  0.12
Coq9Q95X 5.47  1.14*
Coq9R239X 21.44  6.8**,##
The results are represented as fold increase of Coq9 mRNA levels after
cyclohexamide administration. Data are expressed as the mean  SD of five
experiments in triplicates per group. One-way ANOVA with a Tukey post hoc
test. *P < 0.05; **P < 0.01; Coq9Q95X and Coq9R239X mice versus Coq9+/+ mice.
##P < 0.01; Coq9Q95X versus Coq9R239X mice. One-way ANOVA for comparison
between the three experimental groups: P = 0.0022.
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(Supplementary Fig S10A, B, E and F) and pons (Supplementary Fig
S10I, J, M and N) of 12-month-old Coq9Q95X. At 18 months of age,
there was an overall increase of astrocytes proliferation with no
differences between mutants and control animals (Supplementary
Fig S10C, D, G, H, K, L, O and P). Heart evaluation at 12 and
18 months of age did not show any anatomopathological changes
(Supplementary Fig S11I–P).
Female Coq9Q95X mice develop a mild myopathic phenotype with
exercise intolerance
Because the muscle was the most impaired tissue in Coq9Q95X homo-
zygous mice, we assessed the locomotor activity and muscle
strength at 6 months of age. Compared to sex-matched wild-type
controls, Coq9Q95X females showed a significant reduction on the
average speed during the use of the wheel and spontaneous wheel
activity, while there were no differences between mutant and
control male animals (Fig 9A–C). The decrease in the distance trav-
elled in the home-cage running wheels was corroborated by the
observation of reduced spontaneous movement in the open-field test
(Fig 9E). Likewise, the reaches score obtained in the hanging wire
test was lower just in homozygous mutant females (Fig 9D).
However, muscle strength of forelimbs was not affected (Fig 9F).
The life span of Coq9Q95X and Coq9+/+ mice was similar in both
genders.
Effects of oral administration of 2,4-dihydroxybenzoic
acid (2,4-diHB)
As a proof of concept, we also evaluated whether the stability of the
CoQ multiprotein complex would affect a possible bypass therapy.
For that purpose, we treated Coq9+/+, Coq9Q95X and Coq9R239X mice
with oral 2,4-dihydroxybenzoic acid (2,4-diHB), which has been
previously tested as a bypass therapy for Dcoq7 Saccharomyces
cerevisiae strains (Xie et al, 2012; Doimo et al, 2014). After 1 month
of treatment, Coq9Q95X and Coq9+/+ mice showed a reduction of
kidney CoQ9 levels compared with the non-treated littermate
(Fig 10A and B and Supplementary Fig S12A–D). On the contrary,
A B C D
E F G H
Figure 5. Levels of COQ biosynthetic proteins.
A–D Representative Western blot and quantitation of Western blot bands of COQ7 (A), ADCK3 (B), COQ5 (C) and COQ6 (D), and VDAC1 as a loading control in the kidneys
of 3-month-old mice. *P < 0.05; **P < 0.01; ***P < 0.001; Coq9Q95X and Coq9R239X mice versus Coq9+/+ mice. ##P < 0.01; ###P < 0.001; Coq9Q95X versus Coq9R239X
mice. One-way ANOVA with a Tukey’s post hoc test.
E–H Representative Western blot and quantitation of Western blot bands of COQ7 (E), ADCK3 (F), COQ5 (G) and COQ6 (H), and VDAC1 as a loading control in skeletal
muscle of 3-month-old mice. **P < 0.01; ***P < 0.001; Coq9Q95X and Coq9R239X mice versus Coq9+/+ mice. #P < 0.05; ##P < 0.01; Coq9Q95X versus Coq9R239X mice.
Data information: All values are presented as mean  SD. One-way ANOVA with a Tukey’s post hoc test. Numbers above columns indicate P-values of the one-way
ANOVA test. Coq9+/+ mice n = 4; Coq9Q95X and Coq9R239X mice n = 5.
Source data are available online for this figure.
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Coq9R239X mice treated with 2,4-diHB exhibited significantly higher
levels of CoQ9 (184  9.3%) compared with untreated Coq9R239X
mice (Fig 10A and B and Supplementary Fig S12E and F). Interest-
ingly, this increase in CoQ9 levels in Coq9
R239X mice was also
observed in the skin fibroblasts from the patient with the homolog
COQ9R244X molecular defect treated with 2,4-diHB (175.8  5.6%),
while on control fibroblasts, CoQ10 biosynthesis was inhibited by
2,4-diHB supplementation (Fig 10C and D and Supplementary Fig
S12G and H).
The HPLC chromatographs used to quantify the CoQ levels
showed an abnormal peak in Coq9+/+, Coq9Q95X and Coq9R239X mice
treated with 2,4-diHB. The retention time of this additional peak
was 7.5 min. The mass spectral identification of this lipid exhibited
a molecular ion peak of 767.634 [M + H]+ and 789.616 [M + Na]+
(Fig 10I) and could thus be identified as the reduced demethoxy-
ubiquinone 9 (DMQ9H2) (theoretical mass [C53H82O3] = 767.63422
[M + H]+ and 789.61616 [M + Na]+).
Discussion
Primary CoQ10 deficiency is an autosomal recessive condition with
extremely variable age of onset and clinical manifestations. The













Figure 6. Moderate CoQ deficiency in Coq9Q95X mice leads to impaired mitochondrial bioenergetics function.
A–C Mitochondrial CoQ9 levels from cerebrum (A), kidney (B) and skeletal muscle (C) of Coq9
+/+ and Coq9Q95X males and females. n = 8 for each group.
D–F CI+CIII activity in cerebrum (D), kidney (E) and skeletal muscle (F) of male and female Coq9+/+ and Coq9Q95X mice. n = 6 for each group.
G–I CII+CIII activity in cerebrum (G), kidney (H) and skeletal muscle (I) of male and female Coq9+/+ and Coq9Q95X mice. n = 6 for each group.
J–L Blue-native gel electrophoresis (BNGE) followed by immunoblotting analysis of mitochondrial supercomplexes from Coq9+/+ (n = 3) and Coq9Q95X mice (n = 4) at
3 months of age.
Data information: (A–I) Data are expressed as mean  SD. Statistical analyses were performed on Coq9+/+ male mice versus Coq9Q95X male mice and Coq9+/+ female
mice versus Coq9Q95X female mice. **P < 0.01; ***P < 0.001. Student’s t-test. Complex I+III, NADH-cytochrome c reductase; complex II+III, SDH-cytochrome c reductase.
Source data are available online for this figure.
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with mutations in individual genes remains still unclear (Desbats
et al, 2014). In this study, we demonstrate that two different
premature terminations in the COQ9 protein distinctively affect the
levels of other COQ proteins, suggesting that the truncated version
of the COQ9 protein produced in the Coq9R239X mouse model
induces a dominant-negative effect on the multiprotein complex
for CoQ biosynthesis. As a consequence, the Coq9R239X mouse
model has a global reduction in the COQ proteins, which causes
severe CoQ deficiency and clinical phenotype. In contrast, in the
new Coq9Q95X mouse model reported here, the lack of COQ9
protein results in decreased levels of only COQ7 and COQ5
proteins, which leads to moderate CoQ deficiency and a mild mito-
chondrial myopathy, especially evident in females. Therefore, the
stability of this multiprotein complex is a key factor in the CoQ
biosynthesis rate and, consequently, in the degree of the severity
of CoQ deficiency and in the development of a particular clinical
phenotype.
Genetic diseases caused by nonsense or frameshift mutations can
generate premature termination codons, which usually trigger
nonsense-mediated mRNA decay (NMD). This process is considered
to be a surveillance pathway reducing the amount of non-functional
mRNA that would produce truncated proteins with dominant-negative
or deleterious gain-of-function activities (Brogna & Wen, 2009).
Because premature terminations of COQ9 are induced in both mouse
models, Coq9Q95X and Coq9R239X, it was expected a degradation of
Coq9 mRNA by NMD. Accordingly, Coq9 mRNA was undetectable in
cerebrum, kidney and muscle of Coq9Q95X mice. On the contrary,
Coq9 mRNA was detectable in cerebrum and kidney of Coq9R239X
mice, being the levels around 15% of the control values. As in other
genetic diseases (Holbrook et al, 2004; Rio Frio et al, 2008), the low
levels of Coq9 mRNA are due to NMD because the incubation of
Coq9Q95X and Coq9R239X MEFs with the NMD inhibitor cyclohexa-
mide increased the Coq9 mRNA levels. Therefore, the differences in
Coq9 mRNA levels between the two mouse models may account for
differences in the efficiency of the NMD to degrade the Coq9 mRNA
containing two nonsense mutations that cause different premature
terminations (Inoue et al, 2004; Gong et al, 2014). A different
pattern was, however, observed in muscle, where Coq9 mRNA
levels were almost undetectable in both Coq9Q95X and Coq9R239X
mice, suggesting that there is tissue specificity in the efficiency of
NMD. The existence of this tissue specificity of RNA surveillance
has been previously reported in other diseases, for example,
A C
B D
Figure 7. Mitochondrial respiration of Coq9+/+, Coq9Q95X and Coq9R239X mice.
A–D Measurement of phosphorylating respiration (represented as State 3o, in the presence of ADP and substrates) in kidney (A) and skeletal muscle (C) from male and
female Coq9+/+, Coq9Q95X and Coq9R239X mice at 3 months of age. Representative O2 consumption graphic in kidney (B) and skeletal muscle (D) from female Coq9
+/+,
Coq9Q95X and Coq9R239X mice.
Data information: All values are presented as mean  SD. (A, C) *P < 0.05; **P < 0.01; ***P < 0.001; Coq9Q95X and Coq9R239X mice versus Coq9+/+ mice. #P < 0.05;
Coq9Q95X versus Coq9R239X mice. One-way ANOVA with a Tukey’s post hoc test. Numbers above columns indicate P-values of the one-way ANOVA test (n = 3 for each
group).
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osteogenesis imperfecta type I due to premature termination codon
mutations COL1A1 gene (Bateman et al, 2003; Zetoune et al, 2008).
These differences in the efficiency of NMD between tissues are due
to variable expression of the NMD factors (Zetoune et al, 2008) and
contribute to how disease manifests in different tissues (Khajavi
et al, 2006).
In Coq9R239X mice, the residual Coq9 mRNA observed in cere-
brum and kidney from incomplete nonsense-mediated decay is
translated into an aberrant COQ9 protein without the C-terminal
75 amino acid residues of the mature COQ9 protein. This truncated
COQ9 protein may produce a dominant-negative or gain-of-function
effect, as it has been reported in other mitochondrial diseases
(Tyynismaa et al, 2009; Torres-Torronteras et al, 2011). The dele-
terious gain-of-function effect of the truncated COQ9 protein in
Coq9R239X mice affects the stability of the CoQ multiprotein
complex since the overall levels of COQ proteins were lower in
Coq9R239X mice than those measured in Coq9Q95X mice. Accord-
ingly, we propose that the truncation of the COQ9 protein in the
Coq9R239X mouse model would have two consequences: (i) severe
and moderate reduction of COQ7 and COQ5 levels, respectively,
and (ii) destabilization of the multiprotein complex, decreasing
therefore the levels of the other COQ proteins. Similar results in
the levels of COQ proteins were obtained by LC-MS/MS in
Coq9R239X mice (Lohman et al, 2014), as well as in the skin fibro-
blasts belonging to the patient with the homologues COQ9 muta-
tion (COQ9R244X) (Duncan et al, 2009). On the contrary, in the
Coq9Q95X mouse model, the absence of the COQ9 protein only
affects the levels of COQ7 and COQ5 protein and not the integrity
of the multi-subunit complex. While the reason behind the
decrease in COQ5 levels is unclear, the decrease in COQ7 levels
is justified by the direct physical interaction of COQ9–COQ7,
which is needed by COQ9 to expose demethoxyubiquinone, the
substrate for the reaction catalyzed by COQ7 (Garcia-Corzo et al,
2013; Lohman et al, 2014). The different responses of both
mutant mice to the treatment with 2,4-diHB also suggest that
Coq9Q95X mice have a stable CoQ mutiprotein complex that is
able to regulate CoQ biosynthesis and provide mechanisms of
competitive and/or substrate inhibition (Tran & Clarke, 2007;
Quinzii et al, 2012), in contrast to Coq9R239X mice. The differ-
ences found in the levels of COQ proteins between Coq9R239X and
Coq9Q95X mice are also supported by the yeasts studies, where
phenotypes of certain COQ point mutants dramatically differ from
the respective null mutants (Belogrudov et al, 2001; Baba et al,
2004; Tran et al, 2006). Moreover, we observed two tissue-
specific differences in the COQ protein levels: (i) ADCK3 and
COQ6 protein levels were increased only in kidney of Coq9Q95X
mice, and (ii) COQ6 protein level was decreased in skeletal
muscle but not in kidney of Coq9Q95X mice. These divergences
could reflect a tissue-specific regulatory feature of CoQ biosyn-
thesis and CoQ multiprotein complex formation.
The imbalance of the CoQ biosynthetic multiprotein complex
would explain the severe reduction of CoQ levels in Coq9R239X mice
compared to the moderate CoQ deficiency found in Coq9Q95X mice.
The bioenergetics repercussion of having an intermediate CoQ
A B C D
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Figure 8. Histopathology of muscle from female Coq9+/+ and Coq9Q95X mice at 6 and 18 months of age.
A–H Complex II (SDH) and complex IV (COX) histochemistry of triceps surae showing a decreased stain in 18-month-old Coq9Q95X female mice (D, H) in contrast to
normal SDH and COX activity in 6- and 18-month-old Coq9+/+ (A, C, E, G), as well as 6-month-old Coq9Q95X female mice (B, F).
I–L Gomori trichrome stain (TGM) of triceps surae showed no differences between 6- and 18-month-old Coq9+/+ and Coq9Q95X female mice.
M–P Hematoxylin and eosin (H&E) stains of triceps surae did not reveal any structural abnormality.
Data information: Scale bars: 100 lm. n = 3 for each group. Complex IV, cytochrome c oxidase (COX); complex II, succinate dehydrogenase (SDH).
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deficiency was a reduction of CoQ-dependent respiratory complex
I+III activity and mitochondrial respiration in kidney and muscle from
Coq9Q95X females. This decrease was not due to the impairment
on the distribution between free complex III and supercomplex-
associated complex III and may be attributed to the low residual
CoQ levels in these tissues (30% of normal). This proportion of
the complex I+III activity independent of the supercomplex I-III
is supported by our recent study on the effects of ubiquinol-10
supplementation in Coq9R239X mice, which showed that ubiquinol-
10 treatment increases complex I+III activity without increasing the
amount of complex III associated to the supercomplex (Garcia-Corzo
et al, 2014).
Although muscle and kidney of Coq9Q95X mice had the lowest
CoQ content and the most bioenergetics defect, the function and
the histologic structure of the kidneys were not affected. This is
consistent with the previous study on Coq9R239X mice, which do
not manifest kidney disease either (Garcia-Corzo et al, 2013).
However, it remains unclear why Pdss2kd/kd mice develop nephro-
tic syndrome and Coq9 mutant mice do not (Peng et al, 2008;
Quinzii et al, 2013). On the contrary, histochemical evaluation of
muscle revealed an increased number of COX- and SDH-negative
fibers in Coq9Q95X females at 18 months of age, suggestive of a
late-onset mild myopathy. This reduction in the muscle mitochon-
drial energetic activity suggests a skeletal muscle fiber-type
transformation from slow fibers (type I) to fast fibers (type II). The
changes in fiber-type composition were first reported in an experi-
mental model of respiratory chain myopathy as a compensatory
mechanism for the enzymatic deficiency to maintenance muscle
strength via increased recruitment of glycolysis for ATP production,
at the expense of increased energetic cost (Venhoff et al, 2012).
Similar to our results, Sommerville et al (2013) found an increased
frequency of type IIC fibers in morphologically normal muscle
biopsies from 18 patients with CoQ10 deficiency. Moreover, muscles
with a slow/oxidative phenotypic profile contain higher levels of
CoQ than muscles with a fast/glycolytic phenotypic profile
(Nierobisz et al, 2010), suggesting that type I fibers are more
susceptible to CoQ deficiency.
Results from the locomotor activity tests also showed a gender
difference that is correlated to the bioenergetics and histological
findings, that is, Coq9Q95X females, and not males, had reduced
exercise tolerance. Increased susceptibility of female mice to mito-
chondrial myopathy was also observed in a muscle-specific knock-
out mouse model of COX10 (Diaz et al, 2005) and may account to
the effect of testosterone in muscle mass (Schulte-Hostedde et al,
2003). This is consistent with the decreased voluntary activity of
androgen receptor knockout male mice (Rana et al, 2011).
Additionally, it has been reported that the lower levels of CoQ in







Figure 9. Female Coq9Q95X mice develop a mild myopathic phenotype with exercise intolerance.
A–C Voluntary wheel running test. Distance traveled on the wheel and average speed during the use of the wheel were decreased in female Coq9Q95X mice at 6 months
of age (B, C).
D Hanging wire test. Coq9Q95X female mice obtained less reaches score in the ‘fall and reaches’ method.
E Open-field test. Coq9Q95X mice showed a reduction in the average distance traveled in Coq9Q95X female mice at 6 months of age.
F Grip test: Muscle strength was not affected in Coq9Q95X mice at 6 months of age.
Data information: Data are expressed as mean  SD. Statistical analysis was performed on Coq9+/+ male mice versus Coq9Q95X male mice and Coq9+/+ females versus
Coq9Q95X females. *P < 0.05; **P < 0.01 and ***P < 0.001. Student’s t-test. n = 8 for each group.
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myopathy associated to statin consumption (Bhardwaj et al, 2013).
Our results show lower CoQ levels in muscle tissues of females
compared to male mice, supporting the concept of a greater sensi-
tivity of female to CoQ deficiency.
In conclusion, our study provides the first evidence of the exis-
tence of a multiprotein complex for CoQ biosynthesis in mammals
and its importance in determining the degree of CoQ deficiency
and the clinical phenotype. Our study suggests that the presence of
a COQ9-truncated protein because of an incomplete NMD induces
instability of the CoQ mutiprotein complex and contributes in this
way to the genetic and tissue-specific pathomechanisms. Further-
more, our work describes the first mouse model of mitochondrial
myopathy with exercise intolerance associated to CoQ deficiency,
providing new insights to understand the genotype–phenotype
disparity associated to CoQ deficiency. Finally, our results may
have a potential impact on the treatment of this mitochondrial
disorder in two ways: (i) The efficacy of the bypass therapy
recently proposed for primary CoQ deficiency caused by molecular
defects in proteins of the biosynthetic multicomplex may differ
according to the stability of the CoQ multiprotein complex (Xie
et al, 2012; Doimo et al, 2014), and (ii) increasing CoQ levels
above 50% of its normal levels may be enough to avoid a severe
clinical phenotype.
Materials and Methods
Generation of the genetically modified mouse models
The Coq9Q95X mouse model used in this study was generated by the
Wellcome Trust Sanger Institute from ES cell clone EPD0112_2_A09
obtained from the supported KOMP Repository (www.komp.org).
The ‘knockout first’ cassette was inserted into the C57BL/6N genetic
background (project #CSD38115) (Supplementary Fig S13A). Male
heterozygous Coq9Q95X/+ mice (C57BL/6N genetic background)
were crossbred with female Coq9+/+ mice under C57BL/6J genetic
background. Heterozygous Coq9Q95X/+ mice of the offspring were,
consequently, a mix of C57BL/6N and C57BL/6J genetic background
(Supplementary Fig S13B). Thus, Coq9Q95X/+ mice were crossbred
in order to generate Coq9+/+, Coq9Q95X/+ and Coq9Q95X/Q95X
(referred in the article as Coq9Q95X).
The Coq9R239X mouse model was previously generated and char-
acterized under mix of C57BL/6N and C57BL/6J genetic background
(Supplementary Fig S13B) (Garcia-Corzo et al, 2013).
Only homozygous wild-type and mutant mice from both models
were used in the study.
Mice were housed in the Animal Facility of the University of
Granada under an SPF zone with lights on at 7:00 AM and off at
A B
C D
Figure 10. Effects of oral administration of 2,4-dihydroxybenzoic acid (2,4-diHB) in Coq9+/+, Coq9Q95X and Coq9R239X mice and COQ9R244X patient fibroblasts.
A, B Kidney CoQ9 levels in Coq9
+/+, Coq9Q95X and Coq9R239X mice treated with 2,4-diHB (+2,4-diHB) compared with the non-treated littermate (vehicle). Statistical analysis
was performed on +2,4-diHB Coq9+/+, Coq9Q95X and Coq9R239X mice versus vehicle Coq9+/+, Coq9Q95X and Coq9R239X mice, respectively (n = 3 for each group).
C, D CoQ10 levels in COQ9
R244X skin fibroblasts treated with 2,4-DiHB (+2,4-diHB) compared with the non-treated controls (vehicle). Statistical analysis was performed
on +2,4-diHB COQ9R244X versus vehicle COQ9R244X (n = 4 for each group).
Data information: Data are expressed as mean  SD. Student’ t-test. +P < 0.05; ++P < 0.01.
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7:00 PM. Mice had unlimited access to water and rodent chow. All
experiments were performed according to a protocol approved by
the Institutional Animal Care and Use Committee of the University
of Granada (procedures CEEA 2009-254 and 2010-275) and were in
accordance with the European Convention for the Protection of
Vertebrate Animals used for Experimental and Other Scientific
Purposes (CETS #123) and the Spanish law (R.D. 53/2013). Animals
were randomly assigned in experimental groups. Data were
randomly collected and processed as well.
Cells culture and pharmacological treatment
Mouse embryonic fibroblasts (MEFs) from Coq9+/+, Coq9Q95X and
Coq9R239X mice, as well as primary mutant and control fibroblasts,
were grown in high glucose DMEM-GlutaMAX medium supple-
mented with 10% FBS, 1% MEM non-essential amino acids and 1%
antibiotics/ antimycotic. MEFs were treated for 6 h with 28 lg/ml of
cycloheximide (Sigma; from a 5 mg/ml stock solution prepared in
water) (Rio Frio et al, 2008). After treatment, cells were collected
and analyzed.
PCR analyses of regions corresponding to exons 7–11 of Nnt
DNA was extracted from the mice tail tips, and PCR of Nnt gene was
performed as previously described (Mekada et al, 2009). Nnt gene is
complete in the sub-strain C57/BL6N while presents a deletion in
exons 7–11 in the sub-strains C57/BL6J. Therefore, exon 6 was used
to identify the sub-strains C57/BL6J and C57/BL6N, and exon 7 was
used to identify the sub-strain C57/BL6N. To amplify exon 6, we
used the following primers: forward, GGGTTTTCGATTGCTGTCATT;
reverse, AGTCAGCAGCACTCCTCCAT. To amplify exon 7, we used
the following primers: forward, ATTTAGCTGCTGAGGCTGGA;
reverse, GACAAAGACCCGAGAAGCAC.
Proteomic analysis of kidney mitochondria by
high-resolution LC-MS/MS
Mitochondrial isolation was performed as describe elsewhere
(Fernandez-Vizarra et al, 2002). Mitochondrial pellets were solubi-
lized in 200 ll 2% SDS, 100 mM DTT, and 100 mM Tris–HCl, pH
7.4. Proteins were quantified by Bradford, and 50 lg of each
extract was digested by filter-aided sample preparation (FASP)
method. The tryptic extracts from the wild-type samples (Coq9+/+)
were analyzed by high-resolution LC-MS/MS in data-dependent
mode with an inclusion list. All the COQ9 peptides obtained from
the tryptic digestion, in the range from 500 to 4,000, were included
in the list (allowing one missed cleavage). One microgram of
peptide extract was diluted with 20 ll of 5% MeOH: 1% HCOOH
in order to be injected and analyzed by LC-MS/MS. LC-MS/MS
spectra were searched using SEQUEST (Proteome Discoverer v1.4;
ThermoFisher) and the following parameters: peptide mass toler-
ance 10 ppm, fragment tolerance 0.02 Da, enzyme set as trypsin
and allowance up to three missed cleavages, dynamic modification
of methionine oxidation (+ 16 Da) and fixed modification of cyste-
ine carbamidomethylation (+ 57 Da). The database used for
searching was Mus musculus. Peptide identifications were filtered
at 1% FDR using the Percolator algorithm included in the
Proteome Discoverer software.
The MS system used was an LTQ XL Orbitrap (ThermoFisher)
equipped with a nanoESI ion source. A volume of 20 ll from each
sample was loaded into the chromatographic system consisting of a
C18 preconcentration cartridge (Agilent Technologies) connected to
a 15-cm-long, 100 lm i.d. C18 column (Nikkyo Technos Co.). The
separation was done at 0.4 ll/min in a 90-min acetonitrile gradient
from 3 to 40% (solvent A: 0.1% formic acid, solvent B: acetonitrile
0.1% formic acid). The HPLC system was composed of an Agilent
1200 capillary nano pump, a binary pump, a thermostated micro
injector and a micro switch valve. The LTQ XL Orbitrap was oper-
ated in the positive ion mode with a spray voltage of 1.8 kV. The
spectrometric analysis was performed in a data-dependent mode,
acquiring a full scan followed by eight MS/MS scans of the eight
most intense signals detected in the MS scan from the global list.
The full MS (range 400–1,700) was acquired in the Orbitrap with a
resolution of 60,000. The MS/MS spectra were done in the linear–
ion trap. From the data-dependent analysis, six COQ9 peptides of
the protein were characterized. After the characterization, a targeted
method for the analysis of the six detected peptides was designed.
Wild-type samples were used to validate the targeted method.
Quantification of CoQ9 and CoQ10 levels in mice tissues and
mitochondrial fraction
After lipid extraction from homogenized tissues or cultured skin
fibroblasts, CoQ9 and CoQ10 levels were determined via reversed-
phase HPLC coupled to electrochemical (EC) detection (Lopez et al,
2010; Garcia-Corzo et al, 2013). The results were expressed in
ng CoQ/mg prot.
Gene expression analyses
Total cellular RNA from frozen tissue was extracted and electropho-
resed in agarose 1.5% to check RNA integrity. RNA from muscle
and cerebrum samples was extracted with RNeasy Fibrous Tissue
Midi kit (for muscle) and RNeasy Lipid Tissue Mini kit (for cere-
brum) (Qiagen, Hilden, Germany) and treated with RNase-Free
DNase (Qiagen). RNA from kidney samples was extracted with Real
Total RNA Spin Plus Kit (Real). Total RNA was quantified by optical
density at 260/280 nm and was used to generate cDNA with High
Capacity cDNA Reverse Transcription Kit (Applied Biosystems).
Amplification was performed with quantitative real-time PCR, by
standard curve method, with specific Taqman probes (from Applied
Biosystems) for the targeted gene mouse Coq9 (Mm00804236_m1),
Coq7 (Mm00501588_m1), Coq6 (Mm00553570_m1), Coq5
(Mm005018239_m1), Adck3 (mM00469737_m1) and the mouse
Hprt probe as a standard loading control (Mm01545399_m1).
Sample preparation and Western blot analysis in mice tissues
Western blot analyses were performed in cerebrum, kidney and
muscle homogenates. Samples were homogenized in buffer A
(50 mM Tris–HCl, 1% Triton X-100, 1 mM dithiothreitol, pH 7.6,
protease inhibitor cocktail) at 1,100 rpm in a glass–teflon homo-
genizer. Homogenates were sonicated and centrifuged at 1,000 g for
5 min at 4°C, and the resultant supernatant was used for Western blot
analysis. 60 lg of proteins from the sample extracts was
electrophoresed in 12% Mini-PROTEAN TGXTM precast gels (Bio-Rad)
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using the electrophoresis system mini-PROTEAN Tetra Cell (Bio-Rad).
To detect the truncated version of the COQ9 protein in Coq9R239X mice,
70 lg of proteins from mitochondrial samples extracts was prepared
in XT sample buffer+ XT-reducing agent (Bio-Rad) and electrophore-
sed in a 10% CriterionTM XT precast gel (Bio-Rad) using MOPS running
buffer and the electrophoresis system Criterion Cell (Bio-Rad). In all
experiments, proteins were transferred onto PVDF 0.45-lm
membranes using a mini Trans-blot Cell (Bio-rad) or Trans-blot Cell
(Bio-Rad) and probed with target antibodies. Protein–antibody inter-
actions were detected with peroxidase-conjugated horse anti-mouse,
anti-rabbit or anti-goat IgG antibodies using Amersham ECLTM Prime
Western Blotting Detection Reagent (GE Healthcare, Buckingham-
shire, UK). Band quantification was carried out using an Image Station
2000R (Kodak, Spain) and a Kodak 1D 3.6 software. COQ protein band
intensity was normalized to Vdac1, and the data expressed in terms of
percent relative to wild-type mice (Garcia-Corzo et al, 2013).
The following primary antibodies were used: anti-COQ7 (gener-
ously provided by Dr Hekimi, McGill University, Canada),
anti-COQ6 (Santa Cruz Biotechnology, sc-393932), anti-COQ5
(ProteintechTM, 17453-1-AP), anti-ADCK3 (Abnova, M04A) anti-
COQ9 (Santa Cruz, sc-271892), anti-COQ9 (Abcam, ab104189) and
anti-VDAC1 (Abcam, ab14734).
Sample preparation and Western blot analysis in human
skin fibroblasts
About 1 × 105 cells were collected, washed twice with 1× PBS,
homogenated in 1× PBS and sonicated on ice for 10 s. 30 lg of
protein was mixed with 4× LDS sample buffer and 25% DDT. After
denaturation at 55C for 5 min, samples were loaded in 12% SDS–
PAGE gel. Proteins were transferred on PDVF membranes and incu-
bated overnight at 4C with primary antibodies: 1:100 COQ7 rabbit
polyclonal antibody (Thermo Scientific; PA5-25774), 1:100 COQ6
rabbit polyclonal antibody (Abcam; ab128652), 1:100 COQ9 rabbit
polyclonal antibody (Thermo Scientific; PA5-24816), 1:100 COQ5
rabbit polyclonal antibody (Thermo Scientific; PA5-26327), 1:100
COQ8/ADCK3 mouse monoclonal antibody (Abnova; H00056997-
M04A) and 1:1,000 vinculin monoclonal mouse antibody (Abcam
SPM227), used as a loading control. Protein–antibody interaction
was detected by peroxidase-conjugated mouse antibody, peroxi-
dase-conjugated rabbit antibody or peroxidase-conjugated goat anti-
body using ECL Prime Western Blotting Detection Reagents (GE
Healthcare). Band intensity was assessed by Image J.
CoQ-dependent respiratory chain activities
CoQ-dependent respiratory chain activities (CI + III and CII + III)
were measured in submitochondrial particles as described elsewhere
(Kirby et al, 2007; Garcia-Corzo et al, 2013). The results were
expressed in nmol reduced cyt c/min/mg prot.
Evaluation of supercomplex formation by BNGE
BNGE was performed on the mitochondrial fraction from mice tissues.
Mitochondrial isolation was performed as previously described
(Fernandez-Vizarra et al, 2002; Garcia-Corzo et al, 2013). Mitochon-
drial membrane proteins (100 lg) were applied and run on a 3–13%
first-dimension gradient BNGE gel as previously described (Schagger,
2001; Acin-Perez et al, 2008; Garcia-Corzo et al, 2013). After electro-
phoresis, the complexes were electroblotted onto PVDF filters and
sequentially probed with specific antibodies against complex III, anti-
ubiquinol-Cytochrome c Reductase Core Protein I (Abcam, ab110252).
Mitochondrial respiration
To isolate fresh mitochondria, mice were sacrificed and the organs
were extracted rapidly on ice. Muscle (triceps surae and vastus later-
alis) was submerged in 1 mg/ml proteinase K solution for 60 s.
Then, muscle was homogenized (1: 10, w/v) in isolation buffer
(250 mM sucrose, 2 mM EDTA, 10 mM Tris, 0,5% free fatty
acids albumin, pH 7.4) at 800 rpm at 4°C with a glass–teflon homo-
genizer. The homogenate was centrifuged twice at 1,000 g for 5 min
at 4°C, and the supernatant was centrifuged at 23,000 g for 10 min
at 4°C. Then, the mitochondrial pellet was resuspended in 100 ll of
isolation buffer, and a 10 ll aliquot was used for protein determina-
tion. The remaining sample was washed with 900 ll of isolation
buffer and centrifuged at 13,000 g for 3 min at 4°C. The final crude
mitochondrial pellet was resuspended in 90 ll MAS 1× medium
[70 mM sucrose, 220 mM mannitol, 10 mM KH2PO4, 5 mM MgCl2,
2 mM HEPES, 1 mM EGTA and 0.2% (w/v) fatty acid-free BSA, pH
7.2]. Kidney was homogenated (1:10, w/v) in a respiration buffer A
(250 mM sucrose, 0.5 mM Na2EDTA, 10 mM Tris and 1% free fatty
acid albumin) at 800 rpm in a glass–teflon homogenizer. Then,
homogenate was centrifuged at 500 g for 7 min at 4°C, and the
supernatant was centrifuged at 7,800 g for 10 min at 4°C. The pellet
was then resuspended in respiration buffer B (250 mM sucrose,
0.5 mM Na2EDTA and 10 mM Tris), and a 5 ll aliquot was used for
protein determination. The remaining sample was then centrifuged
at 6,000 g for 10 min at 4°C. The pellet was resuspended in buffer A
and centrifuged again at 6,000 g for 10 min at 4°C. The final crude
mitochondrial pellet was re-suspended in 95 ll MAS 1× medium.
Mitochondrial respiration was measured by using an XFe24 Extra-
cellular Flux Analyzer (Seahorse Bioscience) (Rogers et al, 2011).
Mitochondria were first diluted to the needed concentration required
for plating in cold 1× MAS (2.5 lg/well in kidney; 1.5 lg/well in
muscle). Next, 50 ll of mitochondrial suspension was delivered to
each well (except for background correction wells) while the plate
was on ice. The plate was then centrifuged at 2,000 g for 10 min at
4°C. After centrifugation, 450 ll of 1× MAS + substrate (10 mM
succinate, 2 mM malate, 2 mM glutamate and 10 mM pyruvate) was
added to each well. Respiration by the mitochondria was sequen-
tially measured in a coupled state with substrate present (basal respi-
ration or State 2), followed by State 3o (phosphorylating respiration,
in the presence of ADP and substrates); State 4 (non-phosphorylating
or resting respiration) was measured after the addition of oligomycin
when all ADP was consumed, and then maximal uncoupler-stimu-
lated respiration (State 3u). Injections were as follows: port A, 50 ll
of 40 mM ADP (4 mM final); port B, 55 ll of 30 lg/ml oligomycin
(3 lg/ml final); port C, 60 ll of 40 lM FCCP (4 lM final); and
port D, 65 ll of 40 lM antimycin A (4 lM final). All data were
expressed in pmol/min/lg protein.
Histology and immunohistochemistry
Cerebrum, heart and kidney were formalin-fixed and paraffin-
embedded. Multiple sections (4 lm) were deparaffinized with
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xylene and stained with hematoxylin and eosin (H&E), Masson’s
trichrome (TCM), periodic acid–Schiff (PAS) and Luxol fast blue
(LFB) (Garcia-Corzo et al, 2013). Immunohistochemistry was
carried out in the same sections, using the following primary anti-
bodies: glial fibrillary acidic protein or anti-GFAP (Millipore,
MAB360), anti-oligodendrocytes (Millipore, MAB1580) and neuro-
nal class III b-tubulin anti-TUJ1 (Covance, MMS-435P) (Garcia-
Corzo et al, 2013). Dako Animal Research Kit for mouse primary
antibodies (Dako Diagnóstico S.A., Spain) was used for the qualita-
tive identification of antigens by light microscopy. Sections were
examined at 40–400× magnifications with an OLYMPUS CX41
microscope, and the images were scanned under equal light condi-
tions with the CELL A computer program.
Muscle samples (triceps surae) were snap-frozen in isopentane
cooled in liquid nitrogen. Cross sections (8 lm thick) of frozen
muscle were stained for succinate dehydrogenase (SDH) and cyto-
chrome oxidase (COX) activities (Tanji & Bonilla, 2008). Muscle
sections were also stained with hematoxylin–eosin and Gomori
Trichrome to assess muscle fiber area and general morphology
(Tanji & Bonilla, 2008).
Determination of the metabolite profile in urine
Urine samples were collected for 24 h and analyzed in a BS-200
Clinical Chemistry Analyzer (Mindray Medical España S.L., Spain)
at 37°C. The following colorimetric tests were performed: urea
and albumin (Linear Chemicals S.L., Spain) (Garcia-Corzo et al,
2013).
Assessment of the locomotor activity
Locomotor activity was tested in age-matched mice (6 months old)
with a similar averaged body weight. Voluntary wheel running was
assessed in polycarbonate cages (20.5 cm wide × 36.5 cm
long × 14 cm high) with free access to stainless steel activity wheels
(diameter 23 cm; width 5 cm) with a ball-bearing axle (Bioseb,
Boulogne, France). The wheels were connected to a computer that
automatically recorded the distance traveled by the mice per hour of
recording, as well as the duration and speed of every running bout
during the whole recording period. Spontaneous wheel running was
monitored continuously during 48 h, starting at the beginning of the
dark period (20:00 h), and the results obtained in the 2 days of
evaluation were averaged. Animals had food and water available
ad libitum and were trained to the wheels for 1 day before the data
collection period (Cobos et al, 2012).
The open-field test consisted of a square arena in a ground space
of 25 × 25 × 25 cm. Walls were opaque, so the animals could not
see the room. Each mouse was placed in the center of the square
arena between 8 and 9 PM under red light exposure and its move-
ment monitored through the video-tracking system SMART (Pan-
lab S.L., Spain) for 30 min after an adaption period of 30 min
(Pallud et al, 2011). Distance travelled (cm) of each mouse was
quantified (Garcia-Corzo et al, 2013).
Muscle strength was assessed using a computerized grip strength
meter (Model 47200, Ugo-Basile, Varese, Italy). The experimenter
held the mouse gently by the base of the tail, allowing the animal to
grab the metal bar with the forelimbs before being gently pulled
until it released its grip. The peak force of each measurement was
automatically recorded by the device and expressed in grams (g).
The forelimb grip strength of each mouse was measured in duplicate
with at least 1 min between measurements.
For the hanging wire test, we chose the ‘falls and reaches’
method (Raymackers et al, 2003). Mice were subjected to a 180 s
lasting hanging test, during which a ‘reaching’ score is recorded. At
the beginning of the test, each animal was given a reaching score of
0. Animals were suspended by their forelimbs to a 1.5-mm-thick,
55-cm-long metallic wire suspended 45 cm above soft ground, and
then, the timer was started.
The timer was stopped anytime the animal fell and restarted when
it was placed again on the wire until 180 s. If the animal reached one
end of the wire, timer was stopped and ‘reaching’ score was increased
by 1. Results were expressed as the ‘average of reaches score’.
Supplementation with 2,4-diHB
The supplementation procedure in mice consisted of administering
2,4-diHB in the drinking water in a dose of 1 g/kg bw/day. The
treatment started at 1 month of age, and the mice were sacrificed at
2 months of age. The drinking water was changed twice a week.
The supplementation procedure in primary fibroblasts consisted of
administering 0.5 mM or 2.5 mM 2,4-diHB. A control group with
vehicle (DMSO) at the same dose was also studied. Cells were
collected 1 week after the supplementation.
Ultra carrying out liquid chromatography–mass spectrometer
(MS/MS) analysis of intermediate metabolites
Lipid extracts were obtained as described above for the CoQ
quantification. Samples were analyzed using an Acquity Ultra-
Performance liquid chromatography system coupled to a high
definition QTOF SynaptG2 detector of mass spectrometry (MS/MS)
(Waters Corporation). The analytical separation column was a BEH
C18, 1.7 lm, 2.1 × 50 mm column (Waters, Spain). The mobile phase
consisted of methanol and 0.1% formic acid at the constant flow rate
of 0.5 ml/min. Source and probe temperatures were set at 100 and
500°C, respectively. Nitrogen was used as both cone gas (30 l/h)
and desolvation gas (600 l/h). Acquisition range was between 50 and
1,200 uma.
Statistical analysis
All statistical analyses were performed using the GraphPad scientific
software. Data are expressed as the mean  SD of 3–10 experiments
per group. A one-way ANOVA with a Tukey’s post hoc test was used
to compare the differences between three experimental groups.
Studies with two experimental groups were evaluated using
unpaired Student’s t-test. A P-value of 0.05 was considered to be
statistically significant.
Effect size was calculated using the application available in
http://www.biomath.info/power/ttest.htm. Number of animals in
each group were calculated in order to detect gross ~60% changes
in the biomarkers measurements (based upon a = 0.05 and power
of b = 0.8) using the application available in http://www.
biomath.info/power/index.htm. The Gaussian distribution was
checked using GraphPad Software: http://graphpad.com/quickcalcs/
probability1.cfm.
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